HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Coherus BioSciences, maintaining a price target of $12. Analyst Douglas Tsao continues to support the stock, indicating confidence in its potential.
September 16, 2024 | 11:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Coherus BioSciences, maintaining a price target of $12. Analyst Douglas Tsao continues to support the stock, indicating confidence in its potential.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in stock price. The analyst's continued confidence suggests a positive outlook for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100